CR9834A - [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la ezquizofrenia - Google Patents
[1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la ezquizofreniaInfo
- Publication number
- CR9834A CR9834A CR9834A CR9834A CR9834A CR 9834 A CR9834 A CR 9834A CR 9834 A CR9834 A CR 9834A CR 9834 A CR9834 A CR 9834A CR 9834 A CR9834 A CR 9834A
- Authority
- CR
- Costa Rica
- Prior art keywords
- treatment
- ezquizophrenia
- naftiridin
- onas
- related compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Abstract
Esta invencion se refiere a compuestos de la formula 1 en la que G, A, Z, Q, X, Y, R1 y R2 se definen como en la memoria descriptiva, a composiciones farmaceuticas que los contienen y a su uso en el tratamiento de trastornos del sistema nervioso central y de otros trastornos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49737003P | 2003-08-22 | 2003-08-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR9834A true CR9834A (es) | 2008-04-21 |
Family
ID=34216117
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR8254A CR8254A (es) | 2003-08-22 | 2006-02-22 | [1,8] naftidrin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia |
CR9834A CR9834A (es) | 2003-08-22 | 2008-03-27 | [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la ezquizofrenia |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR8254A CR8254A (es) | 2003-08-22 | 2006-02-22 | [1,8] naftidrin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia |
Country Status (36)
Country | Link |
---|---|
US (3) | US7160888B2 (es) |
EP (1) | EP1660497A1 (es) |
JP (1) | JP4034811B2 (es) |
KR (2) | KR100765668B1 (es) |
CN (1) | CN100422181C (es) |
AP (1) | AP2006003525A0 (es) |
AR (1) | AR045386A1 (es) |
AU (1) | AU2004266191B2 (es) |
BR (1) | BRPI0413860A (es) |
CA (1) | CA2538915C (es) |
CR (2) | CR8254A (es) |
CU (1) | CU23464B7 (es) |
EA (1) | EA009645B1 (es) |
EC (1) | ECSP066391A (es) |
GE (1) | GEP20084447B (es) |
GT (1) | GT200500007A (es) |
HK (1) | HK1091815A1 (es) |
HN (1) | HN2004000319A (es) |
IL (1) | IL173439A0 (es) |
IS (1) | IS8267A (es) |
MA (1) | MA28003A1 (es) |
ME (1) | MEP45308A (es) |
MX (1) | MXPA06002070A (es) |
MY (1) | MY140693A (es) |
NL (1) | NL1026892C2 (es) |
NO (1) | NO20060324L (es) |
NZ (1) | NZ545078A (es) |
OA (1) | OA13238A (es) |
PA (1) | PA8609701A1 (es) |
PE (1) | PE20051039A1 (es) |
RS (1) | RS20060129A (es) |
TN (1) | TNSN06063A1 (es) |
TW (1) | TWI298327B (es) |
UA (1) | UA82541C2 (es) |
WO (1) | WO2005019215A1 (es) |
ZA (1) | ZA200601526B (es) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
JP5080716B2 (ja) | 2001-07-20 | 2012-11-21 | サイコジェニックス・インコーポレーテッド | 注意欠陥・多動性障害の治療 |
US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
NZ552409A (en) * | 2004-06-08 | 2010-04-30 | Nsab Af Neurosearch Sweden Ab | New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
US7851629B2 (en) | 2004-06-08 | 2010-12-14 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
DE602005021641D1 (de) | 2004-06-08 | 2010-07-15 | Nsab, Filial Af Neurosearch Sweden Ab | Neue disubstituierte phenylpiperidine und piperazine als modulatoren der dopamin-neurotransmission |
WO2006040155A1 (en) | 2004-10-13 | 2006-04-20 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
FR2877005A1 (fr) * | 2004-10-22 | 2006-04-28 | Bioprojet Soc Civ Ile | Nouveaux derives d'arylpiperazine |
EP1846411A4 (en) | 2005-01-25 | 2010-08-04 | Glaxo Group Ltd | ANTIBACTERIAL ACTIVE SUBSTANCES |
WO2006090273A2 (en) * | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia |
WO2006090272A1 (en) * | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia |
WO2006103559A1 (en) * | 2005-04-01 | 2006-10-05 | Warner-Lambert Company Llc | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia |
AP2007004198A0 (en) * | 2005-04-08 | 2007-10-31 | Pfizer Prod Inc | Bicyclic [3.1.0] heteroaryl amides as type I glycine transport inhibitors |
JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
AR055203A1 (es) * | 2005-08-31 | 2007-08-08 | Otsuka Pharma Co Ltd | Derivados de benzotiofeno con propiedades antipsicoticas |
AU2006302148B2 (en) | 2005-10-07 | 2012-12-06 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kalpha |
SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
KR20080053398A (ko) * | 2005-10-31 | 2008-06-12 | 화이자 프로덕츠 인크. | 7-[4-(4-나프탈렌-1-일-피페라진-1-일)-부톡시]-3,4-디하이드로-1h-[1,8]나프티리딘-2-온의 결정성 염 |
JPWO2007099828A1 (ja) * | 2006-02-23 | 2009-07-16 | 塩野義製薬株式会社 | 環式基で置換された含窒素複素環誘導体 |
WO2007116265A1 (en) * | 2006-03-31 | 2007-10-18 | Pfizer Products Inc. | Process for making a tetrahydro-pyridoazepin-8-one compound |
CA2858520A1 (en) | 2006-05-18 | 2007-11-29 | Pharmacyclics Inc. | Intracellular kinase inhibitors |
PT2074122E (pt) * | 2006-09-15 | 2011-08-24 | Pfizer Prod Inc | Compostos de pirido(2,3-d)-pirimidinona e sua utilização como inibidores de pi3 |
US20100093738A1 (en) * | 2006-10-06 | 2010-04-15 | Basf Se | Fungicidal Compounds and Fungicidal Compositions |
JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
AR063302A1 (es) * | 2006-10-13 | 2009-01-21 | Otsuka Pharma Co Ltd | Derivados de 4-benzo[b]tiofen-4-il-piperazin-1-il con accion antagonista del receptor 5-ht2a de serotonina y receptor de adrenalina alfa1 y agonista parcial del receptor d2, una composicion farmaceutica que lo comprende y un proceso para producirla. |
WO2008084324A1 (en) * | 2007-01-04 | 2008-07-17 | Pfizer Products Inc. | Naphthyridinone compound |
JP4785881B2 (ja) * | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
CL2008001002A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
JP5466147B2 (ja) * | 2007-05-21 | 2014-04-09 | レビバ ファーマシューティカルズ,インコーポレーテッド | キノリノン系非定型抗精神病薬剤の組成物、合成、及び使用方法 |
CL2008001563A1 (es) * | 2007-05-30 | 2008-10-10 | Wyeth6 3 | Compuestos derivados de benzodioxanos condensados con heterociclos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, crisis de panico, entre otras. |
US7928111B2 (en) * | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
BRPI0820985A2 (pt) | 2007-12-18 | 2015-06-16 | Actelion Pharmaceuticals Ltd | Composto derivado de 5-aminociclometil-oxazondin-2-ona, medicamento e composição farmacêutica que os contém e uso dos mesmos |
US8653069B2 (en) | 2008-07-28 | 2014-02-18 | Jiangsu Hengyi Pharmaceutical Co., Ltd. | Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia |
US8586733B2 (en) | 2008-07-31 | 2013-11-19 | Senomyx, Inc. | Processes and intermediates for making sweet taste enhancers |
CN102232078B (zh) | 2008-12-12 | 2014-07-16 | 埃科特莱茵药品有限公司 | 5-氨基-2-(1-羟基-乙基)-四氢吡喃衍生物 |
SG172958A1 (en) * | 2009-01-23 | 2011-08-29 | Takeda Pharmaceutical | Poly (adp-ribose) polymerase (parp) inhibitors |
HUE031053T2 (en) * | 2009-02-26 | 2017-06-28 | Reviva Pharmaceuticals Inc | Preparations, synthesis and methods of application of arylpiperazine derivatives |
JP5732453B2 (ja) | 2009-06-25 | 2015-06-10 | アルカーメス ファーマ アイルランド リミテッド | Nh酸性化合物のプロドラッグ |
DK2445502T4 (da) * | 2009-06-25 | 2022-11-28 | Alkermes Pharma Ireland Ltd | Heterocycliske forbindelser til behandling af neurologiske og psykologiske lidelser |
ES2834973T3 (es) | 2010-05-04 | 2021-06-21 | Alkermes Pharma Ireland Ltd | Procedimiento de síntesis de compuestos de lactama oxidada |
CA2802733C (en) | 2010-06-24 | 2017-11-21 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
US9156822B2 (en) | 2010-07-02 | 2015-10-13 | The University Of North Carolina At Chapel Hill | Functionally selective ligands of dopamine D2 receptors |
AU2011344270A1 (en) | 2010-12-17 | 2013-07-18 | F. Hoffmann-La Roche Ag | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
RU2757859C2 (ru) | 2011-03-18 | 2021-10-21 | Алкермес Фарма Айэленд Лимитед | Фармацевтические композиции, содержащие водонерастворимое антипсихотическое средство и сложные эфиры сорбитана |
JO3227B1 (ar) * | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
US8969337B2 (en) | 2011-12-15 | 2015-03-03 | Alkermes Pharma Ireland Limited | Prodrugs of secondary amine compounds |
US10004807B2 (en) | 2012-03-19 | 2018-06-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
US9993556B2 (en) | 2012-03-19 | 2018-06-12 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty glycerol esters |
WO2013142205A1 (en) | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
CA2869145A1 (en) | 2012-04-04 | 2013-10-10 | IVAX International GmbH | Pharmaceutical compositions for combination therapy |
JP6345651B2 (ja) * | 2012-05-09 | 2018-06-20 | サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. | ヘテロアリール化合物及びその使用方法 |
US9193685B2 (en) | 2012-09-19 | 2015-11-24 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
EP3119399A4 (en) | 2014-03-20 | 2017-09-27 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
CN104785295B (zh) * | 2015-03-18 | 2018-03-06 | 杭州创培信息科技有限公司 | 一种高选择性多巴胺铂炭催化剂的制备方法 |
WO2017003724A1 (en) | 2015-07-01 | 2017-01-05 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
LT3386511T (lt) | 2015-12-10 | 2021-08-25 | Ptc Therapeutics, Inc. | Hantingtono ligos gydymo būdai |
CN106242934A (zh) * | 2016-07-26 | 2016-12-21 | 云南民族大学 | 一种酮的β‑位C‑H键乙酰氧化合成方法 |
EP3634953B1 (en) | 2017-06-05 | 2024-01-03 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
EP3645121A4 (en) | 2017-06-28 | 2021-03-17 | PTC Therapeutics, Inc. | HUNTINGTON'S DISEASE TREATMENT METHODS |
WO2019023278A1 (en) | 2017-07-25 | 2019-01-31 | Crinetics Pharmaceuticals, Inc. | MODULATORS OF SOMATOSTATIN AND USES THEREOF |
WO2019173230A1 (en) | 2018-03-05 | 2019-09-12 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
CA3093189A1 (en) | 2018-03-07 | 2019-09-12 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
US20210009590A1 (en) | 2018-03-27 | 2021-01-14 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
EP3814360A1 (en) | 2018-06-27 | 2021-05-05 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
EP3814357B1 (en) | 2018-06-27 | 2024-05-01 | PTC Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating huntington's disease |
EP3814344A1 (en) | 2018-08-07 | 2021-05-05 | Firmenich Incorporated | 5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof |
AU2019322538B2 (en) | 2018-08-13 | 2021-09-30 | F. Hoffmann-La Roche Ag | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
CN116348458A (zh) | 2019-08-14 | 2023-06-27 | 因赛特公司 | 作为cdk2抑制剂的咪唑基嘧啶基胺化合物 |
BR112022002375A2 (pt) | 2019-09-12 | 2022-07-19 | Hoffmann La Roche | Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl |
US11851426B2 (en) | 2019-10-11 | 2023-12-26 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
CN114634479A (zh) * | 2020-12-16 | 2022-06-17 | 北京盈科瑞创新药物研究有限公司 | 一种派嗪衍生物、其制备方法及应用 |
WO2022212538A1 (en) * | 2021-03-31 | 2022-10-06 | Blueprint Medicines Corporation | Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof |
WO2023186023A1 (zh) * | 2022-03-30 | 2023-10-05 | 苏州旺山旺水生物医药股份有限公司 | 一类n-取代的喹啉酮化合物、其制备方法和用途 |
CN114805081A (zh) * | 2022-05-20 | 2022-07-29 | 都创(上海)医药开发有限公司 | 一种基于微通道连续流技术快速制备1-萘胺的方法 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5649361A (en) | 1979-09-28 | 1981-05-02 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
JPH07165720A (ja) * | 1988-10-31 | 1995-06-27 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤 |
US5006528A (en) * | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
HU207310B (en) | 1988-12-02 | 1993-03-29 | Pfizer | Process for producing aryl-piperidine derivatives |
EP0402644B1 (en) | 1989-05-19 | 1995-08-16 | Hoechst-Roussel Pharmaceuticals Incorporated | N-(aryloxyalkyl)heteroarylpiperidines and -heteroarylpiperazines,a process for their preparation and their use as medicaments |
WO1991000863A1 (en) * | 1989-07-07 | 1991-01-24 | Pfizer Inc. | Heteroaryl piperazine antipsychotic agents |
US5350747A (en) * | 1989-07-07 | 1994-09-27 | Pfizer Inc | Heteroaryl piperazine antipsychotic agents |
US5032598A (en) | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents |
AU645681B2 (en) * | 1991-05-02 | 1994-01-20 | John Wyeth & Brother Limited | Piperazine derivatives |
NZ240863A (en) | 1991-09-11 | 1995-04-27 | Mcneilab Inc | Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof |
US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
WO1994013661A1 (en) | 1992-12-17 | 1994-06-23 | Pfizer Inc. | Substituted pyrazoles as crf antagonists |
WO1994013676A1 (en) | 1992-12-17 | 1994-06-23 | Pfizer Inc. | Pyrrolopyrimidines as crf antagonists |
TW336932B (en) | 1992-12-17 | 1998-07-21 | Pfizer | Amino-substituted pyrazoles |
DK0674624T3 (da) | 1992-12-17 | 1999-09-13 | Pfizer | Pyrazoler med CRF-antagonistisk aktivitet |
TW370529B (en) | 1992-12-17 | 1999-09-21 | Pfizer | Pyrazolopyrimidines |
FR2699918B1 (fr) * | 1992-12-30 | 1995-03-17 | Pf Medicament | Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments. |
JPH07247271A (ja) * | 1994-01-21 | 1995-09-26 | Otsuka Pharmaceut Co Ltd | 3,4−ジヒドロカルボスチリル誘導体 |
FR2731222A1 (fr) | 1995-03-02 | 1996-09-06 | Pf Medicament | Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments |
JP2900130B2 (ja) * | 1995-03-16 | 1999-06-02 | 大塚製薬株式会社 | カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤 |
JP2987484B2 (ja) * | 1995-03-16 | 1999-12-06 | 大塚製薬 株式会社 | カルボスチリル誘導体の製造方法 |
IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
US6114334A (en) | 1995-07-13 | 2000-09-05 | Knoll Aktiengesellschaft | Piperazine derivatives as therapeutic agents |
WO1997014419A1 (en) | 1995-10-20 | 1997-04-24 | Flora Inc. | Transdermal delivery of alpha adrenoceptor blocking agents |
JPH09241161A (ja) | 1996-03-08 | 1997-09-16 | Nippon Shinyaku Co Ltd | 医 薬 |
US5912256A (en) | 1996-06-20 | 1999-06-15 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US6498163B1 (en) | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
US5945422A (en) | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
FR2761071B1 (fr) | 1997-03-20 | 1999-12-03 | Synthelabo | Derives de quinolein-2(1h)-one et de dihydroquinolein-2(1h)- one, leur preparation et leur application en therapeutique |
FR2769912B1 (fr) | 1997-10-16 | 2000-03-10 | Pf Medicament | Nouveaux derives de la 3-oxo- (2h)-1,2,4 triazine leur preparation et leur application en therapeutique humaine |
DE19747063A1 (de) * | 1997-10-24 | 1999-04-29 | Basf Ag | 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung |
US6267784B1 (en) | 1998-05-01 | 2001-07-31 | Benz Research And Development Corporation | Intraocular lens and haptics made of a copolymer |
WO2001046177A1 (en) | 1999-12-20 | 2001-06-28 | Eli Lilly And Company | Benzofuran derivatives |
DE10041574A1 (de) | 2000-08-24 | 2002-03-07 | Merck Patent Gmbh | Chromenonderivate |
WO2002048105A2 (en) | 2000-11-16 | 2002-06-20 | Wyeth | Aryloxy piperidinyl derivatives for the treatment of depression |
GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
AR032641A1 (es) | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
PL365249A1 (en) | 2001-06-29 | 2004-12-27 | H.Lundbeck A/S | Novel heteroaryl derivatives, their preparation and use |
GB0227240D0 (en) | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
TW200507841A (en) | 2003-03-27 | 2005-03-01 | Glaxo Group Ltd | Antibacterial agents |
US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
-
2004
- 2004-07-28 US US10/900,210 patent/US7160888B2/en not_active Expired - Fee Related
- 2004-08-13 CN CNB2004800241500A patent/CN100422181C/zh not_active Expired - Fee Related
- 2004-08-13 AU AU2004266191A patent/AU2004266191B2/en not_active Ceased
- 2004-08-13 MX MXPA06002070A patent/MXPA06002070A/es active IP Right Grant
- 2004-08-13 UA UAA200601890A patent/UA82541C2/uk unknown
- 2004-08-13 WO PCT/IB2004/002665 patent/WO2005019215A1/en active Application Filing
- 2004-08-13 EP EP04744287A patent/EP1660497A1/en not_active Withdrawn
- 2004-08-13 ME MEP-453/08A patent/MEP45308A/xx unknown
- 2004-08-13 CA CA2538915A patent/CA2538915C/en not_active Expired - Fee Related
- 2004-08-13 NZ NZ545078A patent/NZ545078A/en unknown
- 2004-08-13 EA EA200600294A patent/EA009645B1/ru not_active IP Right Cessation
- 2004-08-13 AP AP2006003525A patent/AP2006003525A0/xx unknown
- 2004-08-13 JP JP2006523707A patent/JP4034811B2/ja not_active Expired - Fee Related
- 2004-08-13 BR BRPI0413860-0A patent/BRPI0413860A/pt not_active IP Right Cessation
- 2004-08-13 KR KR1020067003621A patent/KR100765668B1/ko not_active IP Right Cessation
- 2004-08-13 GE GEAP20049246A patent/GEP20084447B/en unknown
- 2004-08-13 OA OA1200600052A patent/OA13238A/en unknown
- 2004-08-13 KR KR1020077009877A patent/KR100801794B1/ko not_active IP Right Cessation
- 2004-08-13 RS RSP-2006/0129A patent/RS20060129A/sr unknown
- 2004-08-18 PE PE2004000796A patent/PE20051039A1/es not_active Application Discontinuation
- 2004-08-20 MY MYPI20043415A patent/MY140693A/en unknown
- 2004-08-20 HN HN2004000319A patent/HN2004000319A/es unknown
- 2004-08-20 TW TW093125196A patent/TWI298327B/zh active
- 2004-08-20 PA PA20048609701A patent/PA8609701A1/es unknown
- 2004-08-20 AR ARP040103006A patent/AR045386A1/es not_active Application Discontinuation
- 2004-08-20 NL NL1026892A patent/NL1026892C2/nl not_active IP Right Cessation
-
2005
- 2005-01-13 GT GT200500007A patent/GT200500007A/es unknown
-
2006
- 2006-01-20 NO NO20060324A patent/NO20060324L/no not_active Application Discontinuation
- 2006-01-26 IS IS8267A patent/IS8267A/is unknown
- 2006-01-30 IL IL173439A patent/IL173439A0/en unknown
- 2006-02-10 CU CU20060028A patent/CU23464B7/es not_active IP Right Cessation
- 2006-02-21 ZA ZA200601526A patent/ZA200601526B/en unknown
- 2006-02-22 MA MA28828A patent/MA28003A1/fr unknown
- 2006-02-22 EC EC2006006391A patent/ECSP066391A/es unknown
- 2006-02-22 CR CR8254A patent/CR8254A/es unknown
- 2006-02-22 TN TNP2006000063A patent/TNSN06063A1/en unknown
- 2006-08-24 US US11/466,828 patent/US20060287310A1/en not_active Abandoned
- 2006-08-24 US US11/466,822 patent/US20060287309A1/en not_active Abandoned
- 2006-11-08 HK HK06112251.3A patent/HK1091815A1/xx not_active IP Right Cessation
-
2008
- 2008-03-27 CR CR9834A patent/CR9834A/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR9834A (es) | [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la ezquizofrenia | |
ECSP055676A (es) | Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia | |
UY28876A1 (es) | Compuestos de morfolina sustituida y composiciones para el tratamiento de trastornos del sistema nervioso central | |
UY28150A1 (es) | Agentes terapeuticos | |
UY28144A1 (es) | Agentes terapéuticos | |
CR10304A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
UY29781A1 (es) | Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos | |
UY30314A1 (es) | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion | |
ECSP088283A (es) | Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
UY28376A1 (es) | Agentes terapéuticos | |
PA8720801A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento de la depresion | |
GT200600161A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos | |
UY28839A1 (es) | Agentes terapeuticos | |
ECSP088366A (es) | 1,2-diarilimidazoles para uso como moduladores de cb1 | |
ECSP088250A (es) | Derivados de pirazol como agentes terapéuticos | |
CR9407A (es) | Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
CR10255A (es) | "nuevas composiciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos" | |
UY27998A1 (es) | Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia | |
CR7735A (es) | Piperizinas heterociclicas sustituidas para el tratamiento de la esquizofrenia | |
PA8657701A1 (es) | Derivado de quinolina, su uso, preparacion y medicamento que lo contiene | |
UY28656A1 (es) | Derivados de indano heterocíclicos sustituidos y compuestos relacionados para el tratamiento de esquizofrenia | |
UY28476A1 (es) | (1,8) naftirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
UY29052A1 (es) | Nuevos inhibidores de la recaptación de norepinefrina de quinoxalinona para el tratamiento de trastornos del sistema nervioso central | |
DOP2003000709A (es) | Piperazinas heterociclicas sustituidas para el tratamiento de la esquizofrenia | |
DOP2004001045A (es) | Derivados de indano heterrociclicos sustituido y compuesto relacionados para el tratamiento de la esquizofrenia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |